Jeffrey Skolnik, M.D.

Dr. Skolnik leads INOVIO’s clinical development programs, focusing on HPV and immuno-oncology DNA medicines. He is a key member of the leadership team overseeing these global clinical assets. Dr. Skolnik has held several leadership positions in Clinical Development and Medical Affairs for AstraZeneca, GSK, and TetraLogic Pharmaceuticals, for both early- and late-stage compounds. Dr. Skolnik is a board-certified pediatric hematologist/oncologist and is an adjunct associate professor at the University of Pennsylvania.

Dr. Skolnik holds a B.A. in Biology from the University of Pennsylvania and an MD from New York University.